<DOC>
	<DOCNO>NCT00866918</DOCNO>
	<brief_summary>This phase III trial study combination chemotherapy see well work treat young patient newly diagnose acute promyelocytic leukemia . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To decrease total anthracycline dose best current publish result standard risk childhood acute promyelocytic leukemia ( APL ) still maintain comparable event-free survival ( EFS ) . SECONDARY OBJECTIVES : I . To assign treatment base risk stratification white blood cell count ( WBC ) diagnosis . II . To estimate induction failure rate , toxic death rate , disease-free survival rate overall survival rate standard high risk APL patient . III . To monitor cardiotoxicity idarubicin/mitoxantrone base regimen . IV . To document toxicity traditional chemotherapy/all-trans retinoic acid ( ATRA ) ( tretinoin ) base regimen combine arsenic trioxide therapy . V. To study relationship Fms-like tyrosine kinase 3 ( FLT3 ) mutation clinical feature outcome APL . VI . To study risk factor pseudotumor cerebri APL . VII . To study relationship early progenitor cell involvement treatment failure FLT3 positive APL . VIII . To compare EFS child enrol AAML0631 EFS child enrol C9710 age 2 21 receive arsenic trioxide . IX . To estimate proportion patient carry cryptic ( 15 ; 17 ) , i.e. , positive promyelocytes . ( PML ) -retinoic acid receptor alpha ( RARA ) fusion transcript polymerase chain reaction ( PCR ) analysis normal chromosome . X . To estimate proportion patient variant RARA partner . XI . To compare outcome patient ( 15 ; 17 ) patient carry ( 15 ; 17 ) chromosomal abnormality . OUTLINE : This multicenter study . Patients treat base risk factor ( standard-risk [ WBC le 10,000/mm^3 ] high-risk [ WBC 10,000/mm^3 high ] ) . INDUCTION THERAPY : STANDARD-RISK : Patients receive tretinoin orally ( PO ) twice daily ( BID ) day 1-30 idarubicin intravenously ( IV ) 15 minute day 3 , 5 , 7 . HIGH-RISK : Patients receive tretinoin PO BID day 1-30 idarubicin IV 15 minute day 1 , 3 , 5 . Patients proceed consolidation therapy one week later blood count recover . CONSOLIDATION THERAPY : CONSOLIDATION 1 : Patients receive arsenic trioxide IV 2 hour day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 tretinoin PO BID day 1-14 . Treatment repeat every 5 week 2 course , follow 2-week break , treatment repeat 2 course . Beginning 1 week later blood count recover , patient proceed consolidation 2 . CONSOLIDATION 2 : Patients receive cytarabine intrathecally ( IT ) day 1 , tretinoin PO BID day 1-14 , high-dose cytarabine IV 3 hour every 12 hour day 1-3 , mitoxantrone hydrochloride IV 15-30 minute day 3 4 . Patients proceed consolidation 3 1 week later blood count recover . CONSOLIDATION 3 : Patients receive cytarabine IT day 1 , tretinoin PO BID day 1-14 , idarubicin IV 15 minute daily day 1 , 3 , 5 . High-risk patient standard-risk patient positive minimal residual disease real-time quantitative ( RQ ) -PCR receive consolidation 4 one week later blood count recover . All standard-risk patient proceed maintenance therapy . CONSOLIDATION 4 ( patient high-risk cytology ) : Patients receive cytarabine IT day 1 , tretinoin PO BID day 1-14 , high-dose cytarabine IV 3 hour every 12 hour day 1-3 , idarubicin IV 15 minute day 4 . Patients demonstrate molecular complete remission ( CR ) remain hematological CR proceed maintenance therapy 1 week later blood count recover . MAINTENANCE THERAPY : Patients receive cytarabine IT day 1 ( course 1 ) , tretinoin PO BID day 1-14 , mercaptopurine PO daily ( QD ) day 1-84 , methotrexate PO day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 . Treatment repeat every 12 week 9 course . After completion study treatment , patient follow every month 1 year , every 3 month 2 year , every 6 month 2 year , annually 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Patients must newly diagnose clinical diagnosis acute promyelocytic leukemia initially morphology ( bone marrow peripheral blood ) ; bone marrow highly preferred case marrow obtain diagnosis , peripheral blood accept ; APL consider hematological emergency treatment initiate quickly possible without wait molecular cytogenetic/fluorescence situ hybridization ( FISH ) confirmation ; patient unable begin receive ATRA timely manner follow presumed diagnosis APL , consideration give initiate ATRA proceed treatment outside AAML0631 protocol ; RQPCR result known time study enrollment , patient must demonstrate PMLRARA and/or RARAPML transcripts RQPCR eligible ; patient without evidence APL bone marrow peripheral blood morphology isolate myeloid sarcoma ( myeloblastoma ; chloroma , include leukemia cutis ) eligible provide ( 15 ; 17 ) translocation document either marrow tumor tissue cytogenetics , FISH , PCR prior study enrollment ; situation , touch prep tumor site evaluate FISH PMLRARA probe ; NOTE : A lumbar puncture require enrol study ; diagnosis APL know suspect , extreme caution must exercise perform lumbar puncture active coagulopathy ; addition compute tomography ( CT ) magnetic resonance imaging ( MRI ) consider rule possibility associate chloroma central nervous system ( CNS ) disease suspect proven ; CNS disease document , patient still eligible No minimal performance status criteria The patient must receive systemic definitive treatment APL suspect leukemia , include cytotoxic chemotherapy , retinoids , arsenic ; prior therapy corticosteroid , hydroxyurea , leukopheresis exclude patient ; patient receive intrathecal cytarabine prior diagnosis APL know , patient still eligible long meet eligibility requirement Pregnant woman nurse mother exclude ; treatment protocol would expose unborn child significant risk ; patient pregnant plan become pregnant treatment ; woman men reproductive potential agree use effective mean birth control ; extremely high risk fetal malformation pregnancy occur ATRA amount even short period Patients preexist prolonged QT Syndrome eligible protocol due use arsenic trioxide prolong QT interval</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>